209 related articles for article (PubMed ID: 26224872)
21. Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review.
Esselen KM; Boruta DM; del Carmen M; Schorge JO; Goodman A; Growdon WB
Int J Gynecol Cancer; 2011 Aug; 21(6):1078-83. PubMed ID: 21633304
[TBL] [Abstract][Full Text] [Related]
22. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
23. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
24. The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study.
Chao X; Wu M; Ma S; Tan X; Zhong S; Bi Y; Wu H; Lang J; Li L
Sci Rep; 2020 Apr; 10(1):5984. PubMed ID: 32249826
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
26. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
27. Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center.
Kato MK; Yoshida H; Uehara T; Uno M; Ishikawa M; Miyasaka N; Kato T
Taiwan J Obstet Gynecol; 2021 Mar; 60(2):238-244. PubMed ID: 33678322
[TBL] [Abstract][Full Text] [Related]
28. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
[No Abstract] [Full Text] [Related]
29. Retrospective analysis of prognostic variables and clinical outcomes in surgically staged intermediate risk endometrial carcinoma.
Zhang GY; Wu LY; Li B; Huang MN; Zhang R; Li XG
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):309-16. PubMed ID: 23540792
[TBL] [Abstract][Full Text] [Related]
30. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Eskander RN; Ali S; Dellinger T; Lankes HA; Randall LM; Ramirez NC; Monk BJ; Walker JL; Eisenhauer E; Hoang BH
Int J Gynecol Cancer; 2016 Jan; 26(1):125-32. PubMed ID: 26397159
[TBL] [Abstract][Full Text] [Related]
31. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
[TBL] [Abstract][Full Text] [Related]
33. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
34. Architectural versus nuclear atypia-defined FIGO grade 2 endometrial endometrioid adenocarcinoma (EEC): a clinicopathologic comparison of 154 cases with clinical follow-up.
Winham WM; Lin D; Stone PJ; Nucci MR; Quick CM
Int J Gynecol Pathol; 2014 Mar; 33(2):120-6. PubMed ID: 24487465
[TBL] [Abstract][Full Text] [Related]
35. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
Huvila J; Laajala TD; Edqvist PH; Mardinoglu A; Talve L; Pontén F; Grénman S; Carpén O; Aittokallio T; Auranen A
Gynecol Oncol; 2018 Apr; 149(1):173-180. PubMed ID: 29486992
[TBL] [Abstract][Full Text] [Related]
36. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
Watari H; Xiong Y; Hassan MK; Sakuragi N
Gynecol Oncol; 2009 Jan; 112(1):229-34. PubMed ID: 19007976
[TBL] [Abstract][Full Text] [Related]
37. DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas.
He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
[TBL] [Abstract][Full Text] [Related]
38. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
39. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
40. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
